[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635423":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":100,"collaborators":102,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":11,"eligibilityCriteria":115,"healthyVolunteers":112,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":11,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":132,"whyStopped":11,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Goserelin group","EXPERIMENTAL",null,[13],"Drug: Goserelin 3.6 MG",{"label":15,"type":16,"description":11,"interventionNames":11},"Control group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Goserelin 3.6 MG","Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to autologous haematopoietic stem cell transplantation conditioning.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"wei shi","CONTACT","86-13207131315","496020121@qq.com",[30,48,63,70,85],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450000","China","CN",{"type":38,"coordinates":39},"Point",[40,41],113.64861,34.75778,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":46,"phoneExt":11,"email":47},"jie wei cao","86-15093360671","15093360671@163.com",{"facility":49,"status":11,"city":50,"state":51,"zip":52,"country":35,"countryCode":36,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430000",{"type":38,"coordinates":54},[55,56],114.26667,30.58333,{"lat":56,"lon":55},[59],{"name":60,"role":26,"phone":61,"phoneExt":11,"email":62},"yang Cao","86-13986142606","13986142606@163.com",{"facility":5,"status":11,"city":50,"state":51,"zip":52,"country":35,"countryCode":36,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},{"type":38,"coordinates":65},[55,56],{"lat":56,"lon":55},[68],{"name":69,"role":26,"phone":27,"phoneExt":11,"email":28},"Wei Shi",{"facility":71,"status":11,"city":72,"state":73,"zip":74,"country":35,"countryCode":36,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"The First People's Hospital of Yunnan Province","Kunming","Yunnan","650000",{"type":38,"coordinates":76},[77,78],102.71833,25.03889,{"lat":78,"lon":77},[81],{"name":82,"role":26,"phone":83,"phoneExt":11,"email":84},"jie ya Wang","86-13211630338","13211630338@163.com",{"facility":86,"status":11,"city":87,"state":88,"zip":89,"country":35,"countryCode":36,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000",{"type":38,"coordinates":91},[92,93],120.16142,30.29365,{"lat":93,"lon":92},[96],{"name":97,"role":26,"phone":98,"phoneExt":11,"email":99},"min yan Zhao","86-15858199217","15858199217@163.com",{"type":101,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[103,105,107,108],{"name":104,"class":6},"Tongji Hospital",{"name":106,"class":6},"Zhejiang University",{"name":31,"class":6},{"name":109,"class":6},"The First People's Hospital of Yunnan","100635423","clinical-study-on-the-preservation-of-ovarian-function-following-autologous-hematopoietic-stem-cell-transplantation-using-goserelin-100635423",false,"NCT07552493","Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin","Inclusion Criteria:\n\n1\\. Haematological patients scheduled for autologous haematopoietic stem cell transplantation; 2. Female patients aged 14 to 50 years with regular menstrual cycles prior to transplantation; 3. Patients or their legal representatives must voluntarily participate and sign an informed consent form, demonstrating comprehension and willingness to comply with all study procedures and requirements; 4. Estimated survival exceeding one year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n1\\. Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; 2. Patients with a history of allergy to goserelin or related medications; 3. Patients who have previously undergone menopause due to physiological or pathological factors; 4. Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; 5. Patients currently participating in other clinical studies that may influence menstrual recovery; 6. Patients who refuse to participate in this clinical study.","FEMALE","14 Years","50 Years",{"count":120,"type":121},64,"ESTIMATED","INTERVENTIONAL",[124],"NA","This study is a prospective, multicenter, randomized controlled clinical trial planned to enroll 64 female hematologic patients aged 14 to 50 years scheduled for autologous hematopoietic stem cell transplantation (auto-HSCT). Participants will be divided into two groups based on the use of myeloablative conditioning: the myeloablative conditioning (MAC) group and the non-MAC conditioning group. The conditioning regimen for autologous hematopoietic stem cell transplantation primarily employs melphalan. A melphalan dose \\>140 mg\u002Fm² constitutes myeloablative conditioning (MAC), while a dose ≤140 mg\u002Fm² is classified as non-myeloablative conditioning. Within each group, patients were randomly assigned 1:1 to the experimental group (goserelin prophylaxis) or control group using a random number table. The experimental group received a single 3.6mg subcutaneous injection of goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group did not receive goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplantation (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Other reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil\u002Fplatelet engraftment; disease recurrence rate; transplant-related mortality; and adverse event (AE) incidence. This study aims to evaluate the efficacy of goserelin in improving ovarian function following autologous hematopoietic stem cell transplantation in hematologic malignancy patients.",[127,128],"Ovarian Insufficiency","Autologous Hematopoietic Stem Cell Transplantation",[130,131],"Autologous haematopoietic stem cell transplantation","Ovarian insufficiency","NOT_YET_RECRUITING","2026-04-20",{"date":135,"type":136},"2026-04-27","ACTUAL",{"date":138,"type":121},"2026-05-01",{"date":140,"type":121},"2027-10-01",{"name":5,"class":6},5]